ProCE Banner Activity

CheckMate 816: Association of Pathologic Features With Efficacy Outcomes for Neoadjuvant Nivolumab + Platinum-Doublet CT in Resectable NSCLC

Slideset Download
Conference Coverage
Results from a post hoc analysis of the CheckMate 816 study showed improved pathologic complete response and EFS with neoadjuvant nivolumab plus platinum-doublet CT in patients with resectable NSCLC regardless of lymph node involvement.

Released: September 16, 2022

Expiration: September 15, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.